CSF3 and hematologic disorder: After 2000, the successful application of haplo-SCT based on immune tolerance induced by granulocyte colony-stimulating factor (G-CSF) and anti-thymocyte globulin (ATG, The Beijing Protocol) and haplo-SCT based on immune tolerance induced by posttransplant cyclophosphamide (PTCy, The Baltimore Protocol) in transplant candidates with hematological diseases (21, 31–36), such as patients with AML, allowed haploidentical allografts to be used worldwide, and it is a reality that almost everyone has a donor (Figure 1).